IMMUMEDIC · European information platform for dendritic cell therapy · No promise of cure
Manufacturing

How are dendritic cells manufactured?

Manufacturing dendritic cells is a laboratory-based, patient-specific process. The exact protocol depends on the responsible manufacturer, the antigen source and the intended treatment concept.

In brief: This information is intended for orientation. An individual treatment decision requires a medical assessment of the diagnosis, alternatives, risks and treatment goals.

Starting material

Suitable immune-cell populations are obtained from a blood collection. Required volume, collection tubes and transport conditions depend on the manufacturing protocol.

Differentiation into dendritic cells

Suitable precursor cells are developed towards dendritic cells under defined culture conditions.

Tumour-related antigen information

Different antigen sources or tumour-related information can be used for immunological targeting. Which source is appropriate depends on the method and the individual clinical situation.

Maturation and function

Maturation steps are intended to support antigen presentation and communication with T cells.

Quality control and release

Before use, product-specific quality and safety criteria are checked. The binding criteria are the release specifications and accompanying documentation of the responsible manufacturing partner.

Transport and handover

After release, transport, storage and application are organised according to the documented specifications. These instructions must not be changed independently.

Editorial context: This material is provided for information, avoids general promises of cure and separates scientific statements from organisational information. Last structural revision: 19 August 2026.
ORIENTATION

Patient or medical professional?

These two pathways are intentionally separated so that enquiries can be directed appropriately.

Call Rita+49 30 439 792 5331